Neuroimaging and genetic influence in treating brain neoplasms
作者： L. Celso Hygino da Cruz , Margareth Kimura
DOI: 10.1016/J.NIC.2014.09.011
关键词:
摘要: The current treatment of glioblastoma patients based on surgery, radiation, and chemotherapy has achieved modest improvement in progression-free survival. In this direction, personalized is the next achievement for better patient management increased overall Genetic characterization high-grade gliomas by MR imaging goal neuroimaging. main genetic alterations described these neoplasms, implications treatment, prognosis are reviewed. features novel techniques correlated with aspects such tumors. Posttreatment phenomena, as pseudoprogression pseudoresponse, analyzed association expression
sci-hub.se 参考文章(56)
Maurizio Salvati, Angelo Pichierri, Manolo Piccirilli, Giacoma Maria Floriana Brunetto, Alessandro D'Elia, Spartaco Artizzu, Francesca Santoro, Antonietta Arcella, Felice Giangaspero, Alessandro Frati, Luca Simione, Antonio Santoro, Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients: Clinical article Journal of Neurosurgery. ,vol. 117, pp. 204- 211 ,(2012) , 10.3171/2012.4.JNS101702
D R Macdonald, T L Cascino, S C Schold, J G Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology. ,vol. 8, pp. 1277- 1280 ,(1990) , 10.1200/JCO.1990.8.7.1277
Qi SongTao, Yu Lei, Gui Si, Ding YanQing, Han HuiXia, Zhang XueLin, Wu LanXiao, Yao Fei, IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma Cancer Science. ,vol. 103, pp. 269- 273 ,(2012) , 10.1111/J.1349-7006.2011.02134.X
Cristo Chaskis, Bart Neyns, Alex Michotte, Mark De Ridder, Hendrik Everaert, Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surgical Neurology. ,vol. 72, pp. 423- 428 ,(2009) , 10.1016/J.SURNEU.2008.09.023
Adam Wu, Kenneth Aldape, Frederick F. Lang, High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors Journal of Neuro-oncology. ,vol. 99, pp. 57- 64 ,(2010) , 10.1007/S11060-009-0100-5
J Dunn, A Baborie, F Alam, K Joyce, M Moxham, R Sibson, D Crooks, D Husband, A Shenoy, A Brodbelt, H Wong, T Liloglou, B Haylock, C Walker, Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. British Journal of Cancer. ,vol. 101, pp. 124- 131 ,(2009) , 10.1038/SJ.BJC.6605127
Tareq A. Juratli, Matthias Kirsch, Katja Robel, Silke Soucek, Kathrin Geiger, Rüdiger von Kummer, Gabriele Schackert, Dietmar Krex, IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. Journal of Neuro-oncology. ,vol. 108, pp. 403- 410 ,(2012) , 10.1007/S11060-012-0844-1
Morteza Esmaeili, Riyas Vettukattil, Tone Frost Bathen, 2-Hydroxyglutarate as a Magnetic Resonance Biomarker for Glioma Subtyping Translational Oncology. ,vol. 6, pp. 92- 98 ,(2013) , 10.1593/TLO.12424
Paul S. Mischel, Timothy F. Cloughesy, Stanley F. Nelson, DNA-microarray analysis of brain cancer: molecular classification for therapy. Nature Reviews Neuroscience. ,vol. 5, pp. 782- 792 ,(2004) , 10.1038/NRN1518
A. D. Norden, G. S. Young, K. Setayesh, A. Muzikansky, R. Klufas, G. L. Ross, A. S. Ciampa, L. G. Ebbeling, B. Levy, J. Drappatz, S. Kesari, P. Y. Wen, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. ,vol. 72, pp. 779- 787 ,(2008) , 10.1212/01.WNL.0000304121.57857.38